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Abstract
Objectives: Mortality in patients starting antiretroviral therapy (ART) is higher in Malawi and Zambia than in South Africa.
We examined whether different monitoring of ART (viral load [VL] in South Africa and CD4 count in Malawi and Zambia)
could explain this mortality difference.
Design:: Mathematical modelling study based on data from ART programmes.
Methods: We used a stochastic simulation model to study the effect of VL monitoring on mortality over 5 years. In baseline
scenario A all parameters were identical between strategies except for more timely and complete detection of treatment
failure with VL monitoring. Additional scenarios introduced delays in switching to second-line ART (scenario B) or higher
virologic failure rates (due to worse adherence) when monitoring was based on CD4 counts only (scenario C). Results are
presented as relative risks (RR) with 95% prediction intervals and percent of observed mortality difference explained.
Results: RRs comparing VL with CD4 cell count monitoring were 0.94 (0.74–1.03) in scenario A, 0.94 (0.77–1.02) with delayed
switching (scenario B) and 0.80 (0.44–1.07) when assuming a 3-times higher rate of failure (scenario C). The observed
mortality at 3 years was 10.9% in Malawi and Zambia and 8.6% in South Africa (absolute difference 2.3%). The percentage of
the mortality difference explained by VL monitoring ranged from 4% (scenario A) to 32% (scenarios B and C combined,
assuming a 3-times higher failure rate). Eleven percent was explained by non-HIV related mortality.
Conclusions: VL monitoring reduces mortality moderately when assuming improved adherence and decreased failure rates.
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Introduction
Since 2003 the number of people receiving antiretroviral
therapy (ART) worldwide has increased 16-fold, with 6.6 million
people on treatment at the end of 2010 [1]. The scale-up of ART
also increased the number of patients experiencing treatment
failure, the need for more expensive second-line regimens, and the
development of viral resistance [2]. Monitoring of patients starting
ART aims to maximize the durability of first-line regimens and to
prevent viral resistance. In industrialized countries patients on
ART have regular measurements of plasma HIV 1-RNA (viral
load, VL) and CD4 cell counts. When drug resistance is suspected,
genotypic or phenotypic resistance tests are done. In resource-
limited settings monitoring of ART is generally based on CD4
counts or clinical monitoring [3]. The World Health Organization
(WHO) has developed clinical and immunologic criteria to detect
treatment failure in the absence of VL monitoring [4]. However,
the accuracy of these criteria is poor: both sensitivities and positive
predictive values of the immunologic and clinical criteria are
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below 50% [5,6]. Therefore, many patients are switched late to
second line ART, or not switched at all [7].
Studies of the effect of routine VL monitoring on mortality have
produced conflicting results. Two randomized trials [8,9] and one
modelling exercise [10] showed that adding VL to CD4 cell count
or clinical monitoring did not significantly improve survival. In
contrast, another modelling study estimated that viral load
monitoring might increase life expectancy by about 10% [11].
We recently compared outcomes between ART programmes in
Southern Africa with and without access to VL monitoring [12].
We found that mortality was about 25% higher in the programmes
in Malawi and Zambia that monitored CD4 counts only,
compared to those from the Republic of South Africa, where
VL is also monitored [12].
VL monitoring should lead to more timely detection of
treatment failure, more effective, targeted adherence counselling
and more appropriate switching to second-line ART, thus
reducing exposure to a failing regimen and improving survival.
In the present study we used a mathematical model to examine the
extent to which the mortality differences observed in patients
starting ART in the different settings in Southern Africa [12]
might be explained by the use of VL monitoring in some
programmes but not others.
Methods
Our study had two components: first we adapted a previous
mathematical model [13] to estimate the causal effect of VL
monitoring on mortality from all causes, compared to CD4 cell
count monitoring only, under different scenarios. In a second step
we examined to what extent VL monitoring could explain the
observed difference in mortality between ART programmes in
South Africa and Zambia and Malawi observed in a previous
analysis [12].
Antiretroviral Treatment Programmes
The International epidemiologic Databases to Evaluate AIDS in
Southern Africa (IeDEA-SA) is a regional collaboration of ART
programmes, which is part of a large international network [14].
Data are collected at ART initiation and each follow-up visit,
using standardized instruments, and transferred in regular
intervals to data centres at the Universities of Cape Town, South
Africa, and Bern, Switzerland. All sites have ethical approval to
collect data and participate in IeDEA-SA. The previous analysis
[12] included four public-sector ART programmes from South
Africa, which monitor VL and CD4 cell counts every 3–6 months
(Khayelitsha [15], Gugulethu [16] and the Tygerberg clinic [17] in
Cape Town, and the Themba Lethu clinic [18] in Johannesburg)
as well as the Lighthouse clinic at Kamuzu Central Hospital in
Lilongwe [19], Malawi, and the Ministry of Health – Centre for
Infectious Disease Research in Zambia (MoH-CIDRZ) pro-
gramme in Lusaka, Zambia [20]. All six programmes trace
patients lost to follow-up (LTFU).
Definitions
First-line ART was defined as a regimen of two nucleoside
reverse transcriptase inhibitors (NRTIs) and one nonnucleoside
reverse transcriptase inhibitor (NNRTI). A switch to a second-line
regimen was defined as a change from the initial NNRTI-based
regimen to a protease inhibitor-based regimen after at least 6
months of follow-up. Virologic treatment failure was defined as
a plasma viral load $1000 copies/ml. Immunologic failure was
defined according to the WHO, as either a CD4 cell count ,100
cells/ml, below baseline or a decrease of at least 50% from the on-
treatment peak value [13]. In case of suspected failure, an
additional measurement (CD4 count or VL, depending on
strategy) was taken 3 months later, and if the corresponding
failure criteria were met again, the patient was classified as failing
treatment at that time. We compared two monitoring strategies:
one where decisions to switch to second-line ART were based on
CD4 counts and another one where decisions were based on VL
monitoring. In both strategies measurements were taken every 6
months.
Mathematical Model
We adapted a previously developed individual-based mathe-
matical model to simulate outcomes after ART initiation in
a cohort of 1000 HIV-infected adult patients [13]. In brief, we
simulated progression events for each patient, including immuno-
logic and virologic failure on first-line ART, switching to second-
line therapy, immunologic and virologic failure on second-line
ART, loss to follow-up (LTFU) and death. Mortality was
separated into HIV-related mortality and non-HIV related
(background) mortality. Mortality estimates are based on the
observed mortality, and virologic and immunologic failures
increase the risk of death independently of each other. Due to
the high LTFU rate, the observed mortality underestimates the
true mortality of patients who started ART [21]. To take this into
account, we obtained corrected mortality estimates where the
mortality among patients LTFU is estimated based on a systematic
review of studies that traced patients LTFU and ascertained their
vital status [21,22]. A more detailed description of the model and
approach to dealing with LTFU is given in the Appendix S1.
The model was parameterized using data from the Khayelitsha
[15] and Gugulethu [16] ART programmes, the two cohorts with
the most complete VL data. Data from the MoH-CIDRZ cohort
in Zambia [20] were used to evaluate switching rates among
patients without VL monitoring. A detailed description of the
dataset including a comparison to the outputs of the model is given
in the Appendix S1. The model parameters and their sources are
shown in Table 1.
Modelling of the Effect of VL Monitoring on Mortality
In the first analysis, we simulated cohorts with identical baseline
characteristics to compare 5-year mortality between VL monitor-
ing and CD4 monitoring. Three scenarios were compared: In
baseline scenario A, we assumed that patients switch to second-line
ART according to the guidelines, i.e. immediately after meeting
the relevant failure criteria. All other parameters including non-
HIV related background mortality were also assumed to be
identical between the two strategies. Any difference in mortality
would thus be due to the ability to detect treatment failure more
accurately when using routine VL compared to CD4 monitoring,
leading to more timely switching to second-line ART.
In scenario B we investigated the effect of reluctance to switch
by introducing a delay from meeting the failure criteria to
switching. Sites without access to VL monitoring tend to have
lower switching rates than sites with regular VL measurements [7].
The times from confirmed failure to switching were estimated
separately from sites with (Gugulethu, Khayelitsha) and without
(MoH-CIDRZ) viral load monitoring.
Lower virologic failure rates as a consequence of better
adherence in sites with routine VL monitoring could also reduce
mortality [23]. In scenario C we therefore increased the risk of the
(unobserved) virologic failure in the CD4 monitoring cohort by
adjusting the scale parameter of the corresponding Weibull
distribution. We investigated the effect of a 2-times and 3-times
higher risk of failure with CD4 count compared to VL monitoring.
Mortality and Routine Viral Load Monitoring
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This range of virologic failure rates was observed in a systematic
review of cross-sectional studies of virologic failure that included
both sites with and without VL monitoring [24].
In all three scenarios baseline characteristics were identical
across strategies and age- and sex-specific background mortality
rates were for Africans living in the Western Cape in 2007 [25].
We assumed that after second line failure no further treatment
options were available. We ran the model 1000 times for both
strategies, sampling the parameters for each run from the
appropriate distribution. The results from the simulations are
Table 1. Model parameters and data sources.
Outcome Source Statistical model Starting Value (95% CI) Dimension Risk
Time to virologic failure
First-line ART; second-
line ART with
immediate switch
Cohorts Parametric Weibull 3 months from
ART start
0.47 (0.43–0.50) Shape 5.6% fail by 1 year after ART
start
3.30 (2.77–3.95) Scale (100 years)
Resistance penalty [11] *) n/a 0.05 (0.00–0.20) Decrease in ART
efficacy
n/a
Time to immunologic failure
After virologic failure Cohorts Parametric
exponential
Virologic failure 0.08 (0.06–0.10) Rate (years21) 7.6% fail by 1 year after
virologic failure
Before virologic failure Cohorts Parametric Weibull 3 months from
ART start
0.22 (0.20–0.25) Shape 3.0% fail by 1 year after ART
start
5.46 (3.14–9.51) Scale (106 years)
Time to death and LTFU
Non-HIV related
mortality, men
ASSA2008 [25] No specific model**) Birth 67 Median (years) 21% die by age of 50
Non-HIV related
mortality, women
ASSA2008 [25] No specific model**) Birth 72 Median (years) 13% die by age of 50
HIV-related observed
mortality
Cohorts and ASSA
2008 [25]***)
Double Weibull****) ART start 0.92 (0.92–0.92) Shape 1 8.4% have died 1 year after
ART start
0.30 (0.30–0.30) Scale 1 (years)
1.00 (1.00–1.00) Shape 2
124.25 (121.27–
127.31)
Scale 2 (years)
0.06 (0.06–0.06) Weight (1st
component)
LTFU Cohorts Double Weibull****) ART start 0.94 (0.94–0.94) Shape 1 4.2% LTFU 1 year after ART
start
1.00 (1.00–1.00) Scale 1 (years)
25.45
(25.45–25.45)
Shape 2
66.19
(66.19–66.19)
Scale 2 (years)
0.07 (0.07–0.07) Weight (1st
component)
Extra hazard after
immunologic failure
Cohorts Cox regression Immunologic failure 1.75 (1.15–2.67) HR, constant over timen/a
Extra hazard after
virologic failure
Cohorts Cox regression Virologic failure 1.07 (0.98–1.18) HR per 3 months on
failing ART
n/a
Observed delay in switching
After virologic failure Cohorts Parametric
exponential
Virologic failure 0.75 (0.63–0.89) Rate (years21) 53% switched 1 year after
virologic failure
After immunologic
failure
Cohorts*****) Parametric
exponential
Immunologic failure 0.06 (0.05–0.08) Rate (years21) 6% switched 1 year after
immunologic failure
Distributions of times to event were assumed to be exponential, Weibull or double Weibull, based on the cohort data. Cohort data are from the Khayelitsha and
Gugulethu ART programmes in Cape Town, South Africa, unless otherwise specified.
CI, confidence interval; ART, antiretroviral therapy; HR, hazard ratio; ASSA, Actuarial Society of South Africa; LTFU, loss to follow-up; n/a, not applicable.
*)Relative decrease in second-line efficacy per year spent on failing first-line ART.
**)Age-specific mortality rates.
***)Non-HIV related mortality estimated from the ASSA2008 model deducted from cohort data on all-cause mortality.
****)Weighted sum of two Weibull distributions.
*****)Data from Ministry of Health-Centre for Infectious Disease Research in Zambia.
doi:10.1371/journal.pone.0057611.t001
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presented as relative risks (RR) of death from all causes with 95%
prediction intervals (PrI) comparing VL with CD4 cell count
monitoring. Estimates of cumulative mortality at 5 years, un-
corrected and corrected for LTFU are also given. We used
a weighted average approach to correct mortality for LTFU [22]
(see Appendix S1 for details).
Comparison of Model Predictions with Observed Data
In the second analysis, we aimed to determine to what extent
VL monitoring could explain the observed difference in mortality
between VL (South Africa) and CD4 (Zambia and Malawi) sites
[12]. We first did a simulation that reflected the situation in the
South African sites, with delays in switching as observed in these
cohorts. We then did a series of simulations where the differences
between Malawi and Zambia and South Africa were introduced
one by one: (i) a 29% higher background mortality [12]; (ii) CD4
monitoring instead of VL monitoring (scenario A); (iii) delay in
switching to second-line ART (scenario B); and additionally
virologic failure rates (iv) 2-times and (v) 3-times higher with CD4
count than with VL monitoring (scenarios B and C combined). For
each simulation, we ran 100 cohort simulations of 1000 patients.
We show Kaplan-Meier curves of mortality, modelled mortality
estimates at different time points, and report the proportion of the
observed difference in mortality between Malawi and Zambia and
South Africa that was explained by the three scenarios.
Results
Modelled Effect of VL Monitoring on Mortality
Scenario A (baseline scenario). The low accuracy of the
WHO immunologic failure criteria meant that only 8% of
virologic failures could be detected by CD4 monitoring within
one year (Table 1). Mortality at 5 years was nevertheless only
slightly lower with VL monitoring compared to CD4 count
monitoring: the relative risk was 0.94 (95% PrI 0.74–1.03).
Cumulative mortality 5 years after the start of ART was 12.3%
(95% PrI 9.8–15.0) with VL monitoring and 13.1% (95% PrI 9.9–
19.3) with CD4 monitoring, assuming that patients switch
immediately after detection of treatment failure (scenario A in
Table 2). Taking into account mortality among patients lost to
follow-up increased these estimates to 16.5% (95% PrI 13.6–19.5)
with VL monitoring and 17.3% (95% PrI 13.9–22.4) with CD4
count monitoring.
Scenario B (delayed switching). The proportion of patients
who switched within one year of meeting relevant failure criteria
was 53% in programmes with routine VL monitoring and 6%
among patients with CD count monitoring (Table 1). Again,
mortality at 5 years was only slightly reduced with VL monitoring:
the RR was 0.94 (95% PrI 0.77–1.02) and cumulative mortality
was 12.6% (9.7–16.7) with routine VL monitoring and 13.5%
(9.7–20.5) with CD4 count monitoring. The corresponding
estimates corrected for loss to follow-up were 16.8% (13.5–20.3)
and 17.6% (13.8–23.7) (scenario B in Table 2).
Scenario C (increased rates of virologic
failure). Assuming a higher rate of virologic failure in the
CD4 monitoring cohort had a more substantial impact (Scenario
C in Table 2): the relative risks comparing VL with CD4
monitoring were 0.86 (0.54–1.05) for a 2-times higher rate and
0.80 (0.44–1.07) for a 3-times higher rate of virologic failure. The
corresponding estimates of corrected mortality in the CD4 cohort
at 5 years were 18.3% (13.5–29.5) and 19.4% (13.6–35.5),
respectively.
Comparisons of Model Predictions with Observed
Mortality
Observed mortality was based on 18 706 adult patients starting
ART in South Africa and 80 937 patients starting ART in Zambia
or Malawi [12]. Patients from viral load sites were more likely to
be women (66% vs. 62%) and had lower CD4 cell counts (93
versus 132 cells/ml) at the start of therapy. In both settings, most
patients started ART with a regimen that combined lamivudine
and stavudine (3TC/d4T) either with nevirapine or efavirenz.
Zidovudine (ZDV), didanosine (ddI) and boosted lopinavir (LPV/
r) was the most common second-line regimen in South Africa,
whereas in Malawi and Zambia, a combination of tenofovir
(TDF), emtricitabine (FTC) and LPV/r was most commonly used.
Modelled mortality and Kaplan-Meier estimates of observed
mortality in the South African VL programmes were 9.1% and
8.6% at 3 years of ART, respectively. In Malawi and Zambia, with
CD4 monitoring only, the corresponding modelled estimates
ranged from 9.5% (scenarios A and B) to 10.1% (scenario B
combined with C, assuming a 3-times higher virologic failure rate).
The Kaplan-Meier estimate of mortality at 3 years in the CD4
monitoring only cohorts was 10.9% (Figure 1). During the first 1.5
years on ART, the modelled mortality was higher than the
observed morality, and little difference was seen between the three
scenarios. After 1.5 years differences in mortality between
modelled scenarios increased gradually.
The absolute difference in observed mortality between Malawi
and Zambia and South Africa was 2.3% (10.9%–8.6%). Approx-
imately 4% of the observed difference in mortality could be
explained by more complete detection of virologic failure with VL
monitoring (Figure 2). The delay from failure to switching
explained only 1% of the difference. When we assumed that VL
monitoring decreased rates of virologic failure (through improved
adherence) the percentage of the mortality difference explained by
viral load monitoring increased to 19% (assuming a 2-times higher
failure rate) or 32% (3-times higher failure rate). Differences in
HIV-unrelated background mortality explained 11% of the
observed difference (Figure 2).
Discussion
We used a mathematical model to estimate the causal effect of
VL monitoring, compared to CD4 count monitoring, on mortality
in ART programmes and to examine to what extent the higher
mortality among patients starting ART in Zambia and Malawi,
compared to South Africa [12], might be explained by the routine
monitoring of VL in South Africa but not in the other two
countries. We found that the relative reduction in mortality
associated with VL monitoring was small (6%) when assuming that
VL monitoring exclusively led to more timely and complete
detection of treatment failure but more substantial (20%) when
also assuming that VL monitoring reduced the rate of virologic
failure. Under the latter scenario up to a third of the absolute
difference in mortality observed between South Africa and Malawi
and Zambia could be attributed to VL monitoring in South Africa.
Possible reasons for the remaining difference include the more
effective management of opportunistic infections and cancers,
including access to intensive care in South Africa [12], differences
in ascertainment of deaths between cohorts, differences in
mortality due to different rates of loss to follow-up and differences
in baseline characteristics.
The results of previous modelling studies of the VL monitoring
and mortality have been heterogeneous. Phillips et al found that
viral load monitoring increased the average survival time in the
first 5 years of ART from 4.09 to 4.14 [10]. This corresponds to
Mortality and Routine Viral Load Monitoring
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a RR of death comparing VL with CD4 count monitoring of
about 0.95 at 5 years. Kimmel et al reported that VL monitoring
increased the life expectancy by 10% as compared to CD4
monitoring. This corresponds to a RR of 0.92 [11]. Our estimated
relative risk of 0.94 is thus in line with the previous studies.
However, we also show that the impact of VL monitoring could be
substantially greater if other benefits such as the reduction in the
risk of virologic failure are considered.
Despite the fact that poor adherence is a major predictor of
virologic failure [26], the effect of VL monitoring on adherence
rates has not been considered in previous modelling studies. In
a large treatment programme in South Africa, the majority of
patients with VL rebounds above 100 copies/ml re-suppressed
viral replication to undetectable levels after a targeted adherence
intervention [23]. As a result, only 2% of patients had virologic
failure after one year of follow-up. We found higher failure rates
with about 6% of patients experiencing virologic failure at one
year, 8% at two years and almost 10% at three years. A systematic
review of ART programmes in sub-Saharan Africa found that the
median percentage of patients experiencing virologic failure
(.1000 copies/ml) was 14% at 3 to 48 months of follow-up
[24]. In a cross-sectional study from Cameroon, where patients
had to pay out of pocket for VL measurements, 16% had a VL
.1000 copies/ml after one year and 23% after 2 years on ART
[27]. Unfortunately different definitions and follow-up durations
hamper more detailed comparisons of rates of virologic failure. In
our model we assumed an up to 3-times higher virologic failure
rate in the absence of VL monitoring. This assumption may seem
strong but it is consistent with the literature.
The effect of VL monitoring on mortality and other outcomes
should ideally be examined in adequately powered randomized
controlled trials. For ethical reasons the protocols of randomized
trials will tend to resemble scenario A in our modelling study,
where trial participants are monitored closely for adherence and
clinical symptoms and thorough adherence counselling is im-
plemented in all groups. Indeed, in the only trial comparing VL
with CD4 count monitoring published so far, all patients were
visited weekly by a trained lay person using a standardized
symptoms questionnaire. Patients were weighed each month and
drugs were replaced weekly using pre-packed storage containers
[8]. This Ugandan trial found no clear benefit of routine VL
monitoring on mortality: the hazard ratio comparing VL with
CD4 count monitoring was 0.93, which is approximately the same
as in the present study when modelling scenario A. Of note, the
trial was not powered to detect or exclude smaller differences in
mortality and confidence intervals around the hazard ratio were
wide (0.59 to 1.45) [8].
A non-inferiority trial in rural district hospitals in Cameroon [9]
that compared clinical and laboratory monitoring (VL and CD4
cell counts every 6 months) with clinical monitoring alone
confirmed the reluctance to switch in the absence of documented
virologic failure observed in cohort studies [7] and modelled in our
study: 13 of 237 patients (6%) in the laboratory group switched to
second-line ART compared to none in the clinical monitoring
group [9]. This is not surprising: when switching patients based on
clinical or immunologic failure criteria many will switch un-
necessarily (i.e. with undetectable VL) [5,28,29]. Second-line
therapy is much more expensive [30], the pill burden generally
higher [4], adverse effects more frequent [31] and second-line
ART is the last treatment option in many settings. Our model
indicates that such reluctance to switch is not, however, associated
with substantially increased mortality.
Table 2. All-cause mortality after five years on antiretroviral therapy (ART) – 1000 simulations of 1000 patients in cohorts with or
without routine viral load monitoring.
Mortality 5 years after ART start (95% prediction
interval)
Risk ratio*** (95% prediction
interval)
Uncorrected* Corrected**
A) Baseline scenario
Viral load monitoring 12.3% (9.8–15.0) 16.5% (13.6–19.5) 0.94 (0.74–1.03)
CD4 cell monitoring 13.1% (9.9–19.3) 17.3% (13.9–22.4) 1
B) Delayed switching
Viral load monitoring 12.6% (9.7–16.7) 16.8% (13.5–20.3) 0.94 (0.77–1.02)
CD4 cell monitoring 13.5% (9.7–20.5) 17.6% (13.8–23.7) 1
C) Higher virologic failure rates with CD4 monitoring
Rate of virologic failure 26higher with CD4 monitoring compared to viral load monitoring:
Viral load monitoring 12.3% (9.8–15.0) 16.5% (13.6–19.5) 0.86 (0.54–1.05)
CD4 cell monitoring 14.2% (9.1–27.0) 18.3% (13.5–29.5) 1
Rate of virologic failure 36higher with CD4 monitoring compared to viral load monitoring:
Viral load monitoring 12.3% (9.8–15.0) 16.5% (13.6–19.5) 0.80 (0.44–1.07)
CD4 cell monitoring 15.4% (9.2–33.5) 19.4% (13.6–35.5) 1
ART, antiretroviral therapy; VL, routine viral load monitoring.
A (baseline scenario): identical virologic failure rates in both monitoring strategies, switch to second-line ART immediately after confirmed failure. B (delayed switching):
identical virologic failure rates in both monitoring strategies, switch to second-line ART after a realistic delay (see Table 1 for parameters). C (higher virologic failure rates
with CD4 monitoring): rate of virologic failure set to be 2 or 3 times higher with CD4 monitoring by adjusting the scale parameter of the Weibull distribution (Table 1),
switch to second-line ART immediately after confirmed failure.
*Uncorrected mortality: mortality based on observed mortality from data.
**Corrected mortality: mortality based on observed mortality, observed LTFU and estimated mortality among patients lost [22].
***Ratios of uncorrected mortality, comparing VL with CD4 monitoring.
doi:10.1371/journal.pone.0057611.t002
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Figure 1. Comparison of all-cause mortality based on model predictions and observed data. Orange lines show Kaplan-Meier estimates
from ART programmes in South Africa, Malawi and Zambia [12] and blue lines the model predictions. Solid lines represent routine viral load
monitoring (South Africa) and broken lines CD4 cell monitoring (Malawi, Zambia).
doi:10.1371/journal.pone.0057611.g001
Figure 2. Possible explanations for the difference in mortality at three years of antiretroviral therapy between South Africa and
Malawi and Zambia. The graph shows the proportion that different causes may contribute to the higher mortality observed in Malawi and Zambia
(CD4 cell count monitoring) compared to South Africa (VL monitoring). The estimates are based on the mathematical model. The effect of a higher
risk of virologic failure in sites with CD4 count monitoring is shown for a 2-times higher risk (dark blue) and 3-times higher risk (light and dark blue
combined).
doi:10.1371/journal.pone.0057611.g002
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The beneficial effect of VL monitoring on adherence may thus
be masked in randomized trials due to intensive counselling and
clinical monitoring in all arms. Furthermore, patients who
participate in clinical trials can generally be expected to be more
adherent than patients treated in routine ART programmes.
Although there are at least two ongoing trials that compare routine
VL to CD4 monitoring [32–33], it is unclear to what extent these
studies will reflect routine care in programmes with and without
access to VL monitoring. More data on levels of adherence and
the rate of virologic failure are thus needed both from routine
programmes and trials.
Our study had several limitations. First, the probability of HIV-
related outcomes in our simulations depended on only two patient-
level factors – virologic and immunologic treatment response. We
thus ignored factors such as age and gender of the patient,
adherence to treatment, resistance mutations, baseline CD4 and
VL values, opportunistic illnesses and co-infections. Although
some of these factors were recorded, we decided to keep the
structure of the model simple. We stress that our results reflect the
situation of the ART programmes included in this study, and may
not apply to other settings. Nevertheless, these cohorts are typical
for adult ART programmes in Southern Africa, with the majority
of patients being women and most patients starting ART with low
CD4 cell counts. Second, we assumed a constant rate of
immunologic failure following virologic failure: we did not have
sufficient data to estimate the progression to immunologic failure
more precisely. Third, we assumed that the hazard of death after
virologic failure increased over time whereas the hazard after
immunologic failure remained constant, in line with previous
studies [34]. In the comparison of model predictions with observed
mortality we did not take differences in baseline characteristics
between the cohorts in South Africa and Malawi and Zambia into
account but examined the crude absolute difference in mortality
observed between the two settings. CD4 cell counts were lower in
the VL sites in South Africa and it is therefore likely that
adjustment for baseline characteristics would have increased this
difference, and reduced the proportion explained by VL
monitoring of ART in South Africa.
We restricted our simulations to two strategies and five years of
follow-up, and did not include costs or the effect on HIV
transmission. Additional strategies could include CD4 monitoring
with targeted VL monitoring (i.e. in patients experiencing
immunologic failure), CD4 or VL monitoring with different
measurement frequencies, or VL monitoring with different failure
thresholds. A recent study confirmed the key role of targeted VL
monitoring to prevent unnecessary switching and to reduce costs
[28] but its impact on survival is probably small. Targeted VL
monitoring will increase switching among virologically failing
patients, which should improve their survival, but the majority of
failing patients would go on undetected. Although the individual
benefits of VL monitoring may be modest, routine VL may have
more substantial benefits in the prevention of new infections and
by limiting the spread of drug resistance. We previously found that
VL monitoring may prevent about 30% of transmission from
treated patients [13].
In conclusion, we have shown that routine VL monitoring can
reduce mortality over the first five years of ART. The magnitude
of this benefit depends on the ability of VL monitoring to improve
adherence and therefore decrease rates of virologic failure. As
point-of-care VL testing will be introduced in programmes in
resource-limited settings in the near future, more research is
urgently needed to improve our understanding of how VL
monitoring impacts on disease progression, the development of
drug resistance and HIV transmission at the individual and
population level.
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